Celldex Therapeutics Announces Poster Presentations of Lead Product Candidates at ASCO Annual Meeting

    PHILLIPSBURG, N.J., May 30 /PRNewswire/ -- Celldex Therapeutics
 announced today that clinical data from studies with its two lead product
 candidates, CDX-110 and CDX-1307, will be presented during poster sessions
 at the 43rd Annual Meeting of the American Society of Clinical Oncology
 (ASCO). The ASCO meeting is being held at McCormick Place in Chicago, IL
 from Friday, June 1 through Tuesday, June 5.
     The CDX-110 poster "Temozolomide as a vaccine adjuvant in GBM" will be
 displayed during the "Central Nervous System Tumors" poster discussion
 session on Sunday, June 3, between 8:00 a.m. and 12:00 p.m.
     The CDX-1307 poster entitled "Antigen presenting cell (APC)-targeted
 hCG Beta vaccine for cancer therapy" will be on display during the
 "Developmental Therapeutics: Immunotherapy" poster discussion session on
 Sunday, June 3 between 2:00 p.m. and 6:00 p.m.
     Both presentations will be on display in location S 102a at their
 respective times.
     About CDX-110
     CDX-110 is an investigational immunotherapy that targets the tumor
 specific molecule EGFRvIII, a functional variant of the epidermal growth
 factor receptor (EGFR), which is a protein that has been well validated as
 a target for cancer therapy. This particular variant, EGFRvIII, was
 discovered in a collaborative effort between Dr. Bert Vogelstein and Dr
 Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke
 University. Unlike EGFR, EGFRvIII is not present in normal tissues,
 suggesting this target will enable the development of a tumor-specific
 therapy for cancer patients. Furthermore, EGFRvIII is a transforming
 oncogene that can directly contribute to cancer cell growth. While
 originally discovered in Glioblastoma Multiforme (GBM), the most common and
 aggressive form of brain cancer, the expression of EGFRvIII has also been
 observed in various other cancers such as breast, ovarian, metastatic
 prostate, colorectal, and head & neck cancers. Celldex has exclusive rights
 to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM
 therapy, as well as in other cancers through additional clinical studies.
     About CDX-1307
     CDX-1307 is our lead Antigen Presenting Cell (APC) Targeting Technology
 product candidate. CDX-1307 is in development for the treatment of
 colorectal, pancreatic, bladder and breast cancers that express the beta
 chain of human chorionic gonadotropin, known as Beta hCG, an antigen often
 found in tumors of these types of cancer. The presence of Beta hCG in these
 cancers correlates with a poor clinical outcome, suggesting that this
 molecule may contribute to tumor growth. Normal adult tissues have minimal
 expression of Beta hCG, therefore, targeted immune responses are not
 expected to generate significant side effects.
     About Celldex Therapeutics, Inc.
     Celldex Therapeutics, Inc. is a biotechnology company focused on
 developing therapeutic vaccines that target and stimulate the body's immune
 system for the treatment of cancer, infectious and autoimmune diseases.
 Celldex has three product candidates already in or about to enter clinical
 development targeting multiple cancers and Hepatitis B. Four additional
 product candidates are in preclinical development for cancer and autoimmune
 disease. Celldex's proprietary technology platform uses fully human
 monoclonal antibodies administered directly to patients to target and
 stimulate dendritic cells - key cells within the immune system. Celldex was
 formed in 2004 as a spin-out from Medarex, Inc. The Company is
 headquartered in Phillipsburg, New Jersey. For more information, please
 visit the website: http://www.celldextherapeutics.com .
 
 

SOURCE Celldex Therapeutics, Inc.